Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Source The Motley Fool

For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound.

Mounjaro and Zepbound are by far Lilly's fastest-growing businesses, and the company's momentum in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days. While weight loss is an enormous opportunity, Lilly has a broad portfolio of medications treating many different pockets of the healthcare landscape.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

Beyond Mounjaro and Zepbound, I'd encourage investors to take a serious look at Lilly's oncology business. Below, I'll explore how the company is quietly making significant strides in treating cancer and make the case for why this could be Lilly's next big opportunity.

How big is the cancer market?

According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 -- more than double its estimated value today.

When it comes to treating cancer, I wouldn't be surprised if names such as Pfizer, Bristol-Myers Squibb, or Merck come to mind first. But believe it or not, Lilly has a flourishing oncology operation in its portfolio. In my eyes, this area of the company is being completely overshadowed by Mounjaro and Zepbound.

Image source: Getty Images.

How is Lilly treating cancer?

Through the third quarter of 2024, Lilly generated total revenue of $31.5 billion -- an increase of 27% year over year. Roughly $15 billion of this total stems from just three drugs -- Mounjaro, Zepbound, and Trulicity. All of these are medications in Lilly's weight loss portfolio.

However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept. 30, sales from Verzenio topped $3.7 billion and grew 38% year over year. The subtle idea I'd like to point out here is that Verzenio alone is growing at a much more accelerated rate than Lilly's business as a whole.

One of the primary drivers for Verzenio's performance is an expanded indication the drug was granted from the Food and Drug Administration (FDA) back in March 2023. While this is all great news for Verzenio, Lilly isn't stopping its ambitions in oncology care with just one treatment.

Right now, the company has seven clinical trials underway exploring new molecules and applications in the cancer market. To further bolster its pursuit of becoming a leading player in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion.

Lilly's long-term potential doesn't hinge on GLP-1 treatments

Since the company reported third-quarter earnings in late October, shares of Lilly have dropped by about 13%.

The primary reason the stock has been sliding is due to some inconsistent growth trends between Mounjaro and Zepbound over the last quarter. But as I pointed out in this piece, even with some turbulence between supply and demand, Mounjaro and Zepbound are still on pace for a record performance in Q4 -- despite falling short of Wall Street's aggressive targets.

It's for this very reason that I encourage investors to look beyond weight loss when it comes to an investment in Eli Lilly. The company is well diversified and is witnessing notable success in areas outside of the GLP-1 realm.

Verzenio's performance in 2024 underscores how expanded indications for medications can accelerate their performance and help contribute to the overall picture in a meaningful way. To me, oncology represents a hugely important new area for Lilly, and one that is ripe for disruption given the size of the addressable market.

I think the company's clinical pipeline and recent acquisition from Scorpion really drive home the point that Lilly's management is thinking much farther into the future, well beyond where the GLP-1 business can go.

Should you invest $1,000 in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $902,242!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of January 21, 2025

Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Bristol Myers Squibb, Merck, and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Fed hike odds near 90% into Wednesday's decision — how to trade the dollar, gold and the S&P 500 A 0.3% monthly core CPI print has lifted the market-implied probability of a 25bp Fed hike on 16 September to roughly 86.5% ~ 90%, which would be the first increase since July 2023. Here is the decision timeline, the pricing versus the forecasts, both scenarios, and the key levels for the dollar, gold and the S&P 500.

Author Suzie

Sep 14, Mon

A 0.3% monthly core CPI print has lifted the market-implied probability of a 25bp Fed hike on 16 September to roughly 86.5% ~ 90%, which would be the first increase since July 2023. Here is the decision timeline, the pricing versus the forecasts, both scenarios, and the key levels for the dollar, gold and the S&P 500.

Gold falls below $4,300 as higher US yields bolster Fed rate hike bets Gold price (XAU/USD) tumbles to near $4,295 during the early Asian session on Tuesday. The precious metal faces some selling pressure as rising bond yields and surging energy prices strengthen expectations that the US Federal Reserve (Fed) will raise interest rates this week.

Author FXStreet

Yesterday 01: 23

Gold price (XAU/USD) tumbles to near $4,295 during the early Asian session on Tuesday. The precious metal faces some selling pressure as rising bond yields and surging energy prices strengthen expectations that the US Federal Reserve (Fed) will raise interest rates this week.

【Daily Brief】10-year Treasury yield briefly tops 5%, S&P 500 slips to 7,602 and the dollar firms at 99.3 as the Fed's decision eve begins The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.

Author Irene Q.

Yesterday 08: 16

The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.

Silver breaks $64 as precious metals rebound — can gold hold the $4,280 line into the Fed decision?Silver has climbed back above $64 an ounce for the first time this week, leading a broad rebound across precious metals hours before the Federal Reserve delivers what is expected to be its first rate hike since 2023. Spot silver was last at $64.64, up 1.49% on the day, while gold reclaimed $4,300 and platinum and palladium both advanced. The question now is whether the bounce is a genuine turn — or a pause before the Fed's dot plot decides the next move.

Author Suzie

7 hours ago

Silver has climbed back above $64 an ounce for the first time this week, leading a broad rebound across precious metals hours before the Federal Reserve delivers what is expected to be its first rate hike since 2023. Spot silver was last at $64.64, up 1.49% on the day, while gold reclaimed $4,300 and platinum and palladium both advanced. The question now is whether the bounce is a genuine turn — or a pause before the Fed's dot plot decides the next move.

Bitcoin falls below $75,000 as the CLARITY Act fails in the Senate — what the vote means for crypto The US Senate blocked the Digital Asset Market CLARITY Act in a 49-50 procedural vote, sending Bitcoin briefly below $75,000 — its biggest one-day drop since June. Ethereum fell more than 8%, Coinbase slid 10% and $75 billion of crypto market value evaporated. Here is what the vote was, why it failed, and the levels that matter now.

Author Suzie

6 hours ago

The US Senate blocked the Digital Asset Market CLARITY Act in a 49-50 procedural vote, sending Bitcoin briefly below $75,000 — its biggest one-day drop since June. Ethereum fell more than 8%, Coinbase slid 10% and $75 billion of crypto market value evaporated. Here is what the vote was, why it failed, and the levels that matter now.

Popular Symbols